title: Monitoring of peripheral blood cytotoxic T-cells under fluvastatin treatment in renal transplant recipients.
abstract: Flow cytometric T-cell analysis is capable of adding valuable information for balancing immunosuppression in transplant recipients as it can take into account individual effects of immunosuppressive drugs on each patient as well as effects of other drugs which may modify the overall immunosuppression. Studies suggest that HMG-CoA-reductase-inhibitors (statins) reduce the frequency of organ rejection, although the precise mechanism of this effect is unknown. We therefore evaluated the effect of fluvastatin on size and activation of T-cell subpopulations and NK-cell activity in renal transplant recipients. At baseline, the population size of activated (HLA-DR+) T-cells was negatively correlated to serum HDL cholesterol suggesting an increased T-cell activation at low HDL levels. Fluvastatin treatment of a hypercholesterolemic group of patients for two months significantly decreased the LDL cholesterol. A longitudinal analysis revealed a relative increase in non-MHC restricted cytotoxic T-cells (CD3+/CD16+ or CD56+) over time which was significantly attenuated in fluvastatin treated patients but not in normocholesterolemic controls. Moreover, a relative decrease of activated MHC class I-restricted cytotoxic CD8+ T-cells was only observed upon fluvastatin treatment. NK-cell number and activity did not differ between groups. In summary, fluvastatin treatment of hypercholesterolemic renal transplant recipients is associated with a specific modulation of T-cells exerting cytotoxic effector functions.
authors.affiliation: Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Barlage
authors.forename: I A
authors.initials: IA
authors.lastname: Hauser
authors.forename: R
authors.initials: R
authors.lastname: Elbracht
authors.forename: C
authors.initials: C
authors.lastname: Abletshauser
authors.forename: R E
authors.initials: RE
authors.lastname: Schmieder
authors.forename: G
authors.initials: G
authors.lastname: Weidinger
authors.forename: K J
authors.initials: KJ
authors.lastname: Lackner
authors.forename: G
authors.initials: G
authors.lastname: Rothe
authors.forename: G
authors.initials: G
authors.lastname: Schmitz
mesh_terms: D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D000077340:Fluvastatin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology*; D016030:Kidney Transplantation / Q000276:immunology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000276:immunology*
chemical_list: D008076:Cholesterol, HDL; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin